ips细胞临床应用诸多限制

成成爱学习

Molecular Obstacles to Clinical Translation of iPSCs

成成爱学习

值得学习

yingfeixiang

没有内容

yingfeixiang

回复 成成爱学习 的帖子( E' \+ B( G* q+ p; U" l& _

+ }7 Z1 z* O9 {, @看看

sunsong7

Cell Stem Cell. 2016 Sep 1;19(3):298-309. doi: 10.1016/j.stem.2016.06.017. Epub 2016 Jul 21.
" A( B% U" P! s8 Z* yMolecular Obstacles to Clinical Translation of iPSCs.8 }4 P6 E8 }6 {' _) m/ z% d
, `% v5 d$ D9 J$ z+ o  I2 M
The ability to reprogram somatic cells into induced pluripotent stem cells (iPSCs) using defined factors provides new tools for biomedical research. However, some iPSC clones display tumorigenic and immunogenic potential, thus raising concerns about their utility and safety in the clinical setting. Furthermore, variability in iPSC differentiation potential has also been described. Here we discuss whether these therapeutic obstacles are specific to transcription-factor-mediated reprogramming or inherent to every cellular reprogramming method. Finally, we address whether a better understanding of the mechanism underlying the reprogramming process might improve the fidelity of reprogramming and, therefore, the iPSC quality.
0 w; P9 e- }# [8 P7 sCopyright © 2016 Elsevier Inc. All rights reserved.# D& T1 m6 E( d: t5 F$ q+ g, k

9 i+ ~; \. s- UPMID: 27452174 DOI: 10.1016/j.stem.2016.06.0171 |3 H+ N7 _  y5 P) S) P
& H6 w9 h. Y2 B! l& M9 v$ p5 L
- j  V# U9 O# v2 Z4 H' y, c- `9 l5 q" j

sunsong7

回复 成成爱学习 的帖子
4 U. e/ E+ U, w% T2 I6 t  F  _4 A2 ]3 S( d) ]; u* b
已上传